Quest Diagnostics Incorporated

DGX Healthcare Medical - Diagnostics & Research NYSE

Back to Search

$199.21

$-4.77 (-2.34%)

Open: $203.76 | High: $203.78 | Low: $199.04 | Prev Close: $203.98

Market Cap: $22.16B

Volume: 1.1M | Avg: 1.0M

Last updated: March 09, 2026 at 02:01 AM
Investment Rating
B+

Neutral

Overall Score: 60/100

Rating Breakdown:
DCF Score 4/5
80%
Buy
ROE Score 4/5
80%
Buy
ROA Score 4/5
80%
Buy
D/E Score 1/5
20%
Strong Sell
P/E Score 2/5
40%
Sell
P/B Score 3/5
60%
Neutral
Add to Watchlist Add to Portfolio
Stock Score Analysis
C

Stock Score: 592

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 45
Financial Health 55
Growth 60
Market Sentiment 10
Risk 40
Lower is better
Valuation 27
Momentum 55
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 22.77
P/B Ratio 3.08
P/S Ratio 2.01
EPS $8.75
Beta 0.63
Shares Outstanding 111.24M
Price Range & Moving Averages
52-Week High $213.50
52-Week Low $157.20
SMA 50 $190.85
SMA 200 $182.17
Dividend Information
Dividend Yield 1.61%
Annual Dividend $3.20
Earnings
Next Earnings April 21, 2026 12:30 PM ET
Financial Ratios
Margins
Gross Margin 33.2%
Operating Margin 14.1%
Net Margin 9.0%
Returns
ROE 13.9%
ROA 6.1%
Liquidity & Leverage
Debt/Equity 0.96
Current Ratio 1.04
Quick Ratio 0.96
Balance Sheet
Total Assets $16.23B
Total Liabilities $8.94B
Total Equity $7.17B
Cash $420.00M
Total Debt $6.92B
Net Debt $6.50B
Income Statement
Revenue $11.04B
Gross Profit $3.52B
Operating Income $1.60B
Net Income $992.00M
EBITDA $2.19B
Revenue/Share $99.41
Cash Flow
Operating CF $1.89B
CapEx $527.00M
Free Cash Flow $1.36B
Book Value/Share $65.64
Tangible Book/Share $-29.68
Equity/Share $64.59
Technical Indicators
RSI (14) 42.71 Neutral
MACD
4.46 Signal: 5.60
Volatility 32.82%
Trading Signal Bearish
Performance & Returns
Total Returns
1 Year +11.84%
Risk-Adjusted Returns
Sharpe Ratio 0.57 Fair
Volatility (Ann.) 24.21% Moderate
vs S&P 500 (SPY)
DGX (1Y) +11.84%
S&P 500 (1Y) +13.03%
Alpha (Excess Return) -1.19%
Risk-free rate: 4.5% (3-month US Treasury) • Based on 199 trading days
Sector Comparison (Healthcare)
Compared to 52 peers in Healthcare
Metric DGX Sector Avg Percentile
P/E Ratio 22.77 27.75 40%
P/B Ratio 3.08 -19.58 53%
ROE (%) 13.88% -9.55% 55%
Net Margin (%) 8.99% 9.32% 42%
Stock Score 592 542.0 68%
1Y Return (%) +11.84 % +8.07 % 60%
Percentile: 0% = worst in sector, 100% = best in sector
📊 Historical Price Analysis (Last 200 Days)

Loading chart...

Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
DGX $199.21 $206.71 $207.99 $206.71 $190.75 $182.15 42.71 4.46 32.82% 145255 Weak Short Price Below SMAs
Candlestick Patterns

There wasn't any recognizable pattern for the DGX stock

News Sentiment
📊 Ticker 📰 Headline 💭 Sentiment 📡 Source 🔗 URL
DGX Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term Neutral zacks.com Read More
DGX Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors Neutral prnewswire.com Read More
DGX Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound? Neutral zacks.com Read More
DGX Quest Diagnostics Incorporated (DGX) Presents at Leerink Global Healthcare Conference 2026 Transcript Neutral seekingalpha.com Read More
DGX Should You Continue to Hold DGX Stock in Your Portfolio? Neutral zacks.com Read More
Recent Insider Trading

No recent insider trading data available for DGX

Company Information

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

CEO James E. Davis
Employees 55000
Country US
IPO Date 1996-12-17
Exchange NYSE
Website https://www.questdiagnostics.com
Sector Healthcare
Industry Medical - Diagnostics & Research
Similar Stocks (Healthcare - Medical - Diagnostics & Research)
DHR

Danaher Corporation

Price: $195.50
Change: -3.22%
Market Cap: $1382B
P/E: 38.94
Score: E (512)
View Details
IDXX

IDEXX Laboratories, Inc.

Price: $608.41
Change: -1.70%
Market Cap: $4858B
P/E: 46.51
Score: D (566)
View Details
A

Agilent Technologies, Inc.

Price: $115.07
Change: -2.57%
Market Cap: $3254B
P/E: 25.40
Score: D (535)
View Details
IQV

IQVIA Holdings Inc.

Price: $174.45
Change: -2.27%
Market Cap: $2970B
P/E: 22.25
Score: E (425)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.